Atomoxetine Hydrochloride: Clinical Drug-Drug Interaction Prediction and Outcome

2003 ◽  
Vol 308 (2) ◽  
pp. 410-418 ◽  
Author(s):  
John-Michael Sauer ◽  
Amanda J. Long ◽  
Barbara Ring ◽  
Jennifer S. Gillespie ◽  
Nathan P. Sanburn ◽  
...  
2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Narjes Rohani ◽  
Changiz Eslahchi

Abstract Drug-Drug Interaction (DDI) prediction is one of the most critical issues in drug development and health. Proposing appropriate computational methods for predicting unknown DDI with high precision is challenging. We proposed "NDD: Neural network-based method for drug-drug interaction prediction" for predicting unknown DDIs using various information about drugs. Multiple drug similarities based on drug substructure, target, side effect, off-label side effect, pathway, transporter, and indication data are calculated. At first, NDD uses a heuristic similarity selection process and then integrates the selected similarities with a nonlinear similarity fusion method to achieve high-level features. Afterward, it uses a neural network for interaction prediction. The similarity selection and similarity integration parts of NDD have been proposed in previous studies of other problems. Our novelty is to combine these parts with new neural network architecture and apply these approaches in the context of DDI prediction. We compared NDD with six machine learning classifiers and six state-of-the-art graph-based methods on three benchmark datasets. NDD achieved superior performance in cross-validation with AUPR ranging from 0.830 to 0.947, AUC from 0.954 to 0.994 and F-measure from 0.772 to 0.902. Moreover, cumulative evidence in case studies on numerous drug pairs, further confirm the ability of NDD to predict unknown DDIs. The evaluations corroborate that NDD is an efficient method for predicting unknown DDIs. The data and implementation of NDD are available at https://github.com/nrohani/NDD.


2019 ◽  
Vol 12 (5) ◽  
pp. 513-518 ◽  
Author(s):  
Naoyuki Otani ◽  
Hirokazu Wakuda ◽  
Hiromitsu Imai ◽  
Masae Kuranari ◽  
Yasuyuki Ishii ◽  
...  

Author(s):  
Diana L. Shuster ◽  
Gina Pastino ◽  
Dirk Cerneus

: Cannabis has become legal in much of the United States similarly to many other countries, for either recreational or medical use. The use of cannabis products is rapidly increasing while the body of knowledge of its myriad of effects still lags. In vitro and clinical data show that cannabis’ main constituents, delta-9-tetrahydrocannabinol and cannabidiol, can affect the pharmacokinetics (PK), safety and pharmacodynamics (PD) of other drugs. Within the context of clinical drug development, the widespread and frequent use of cannabis products has essentially created another special population; that is, the cannabis user. We propose that all clinical drug development programs include a Phase 1 study to assess the drug-drug interaction potential of cannabis as a precipitant on the PK, safety and if applicable, the PD of all new molecular entities (NMEs) in a combination of healthy adult subjects as well as frequent and infrequent cannabis users. This data should be required to inform drug labeling and aid health care providers in treating any patient, as cannabis has quickly become another common concomitant medication and cannabis users, a new special population.


2018 ◽  
Vol 104 (5) ◽  
pp. 781-784 ◽  
Author(s):  
Maciej J. Zamek-Gliszczynski ◽  
Xiaoyan Chu ◽  
Jack A. Cook ◽  
Joseph M. Custodio ◽  
Aleksandra Galetin ◽  
...  

Author(s):  
Bri Bumgardner ◽  
Farhan Tanvir ◽  
Khaled Mohammed Saifuddin ◽  
Esra Akbas

Sign in / Sign up

Export Citation Format

Share Document